ストックスクリーナーアプリを入手
84.75
0.06%
0.05
アフターアワーズ：
84.75
Crinetics Pharmaceuticals Inc (CRNX) 最新ニュース
Crinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 52-Week HighTime to Buy? - MarketBeat
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc.CRNX - marketscreener.com
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - AOL.com
Bank of America Corp DE Sells 85,189 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
CRNX (Crinetics Pharmaceuticals) EV-to-OCF : -18.52 (As of Aug. 16, 2026) - GuruFocus
Quantinno Capital Management LP Buys 24,878 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today? - Stocktwits
Vertex-Crinetics pharma merger cleared in US, Germany, Austria, Australia - MLex
Form 8K Crinetics Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria
Crinetics Pharmaceuticals merger with Vertex Pharmaceuticals advances after regulatory clearances - Investing.com
Vertex to acquire Crinetics after HSR clearance; closing expected early Sept - TradingView
Crinetics Pharmaceuticals (CRNX) advances Vertex merger after key antitrust milestones - Stock Titan
How (CRNX) Movements Inform Risk Allocation Models - Stock Traders Daily
Crinetics Pharmaceuticals (CRNX): Wellington reports 7.13M-share, 6.76% ownership - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vertex-Crinetics Pharmaceuticals deal receives clearance in Australia - MLex
Crinetics Pharmaceuticals stock hits all-time high at 84.35 USD By Investing.com - Investing.com Nigeria
Crinetics Pharmaceuticals stock hits all-time high at 84.35 USD - Investing.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 12-Month HighWhat's Next? - MarketBeat
Weekly Recap: Vertex $10B deal, guidance paused and Q2 loss — Crinetics - TradingView
First Trust Advisors LP Raises Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
California State Teachers Retirement System Boosts Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals Inc (CRNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FARALLON CAPITAL MANAGEMENT LLC Adds to Crinetics Pharmaceutical - GuruFocus
Crinetics Pharmaceuticals (NASDAQ: CRNX) sees 1.4% stake reported by FMR LLC - Stock Titan
Crinetics Pharmaceuticals, Inc. $CRNX Shares Bought by Glenmede Trust Co. NA - MarketBeat
Crinetics Pharmaceuticals (CRNX) Stock Looks Rich On Book Value But Reasonable On Deal Value - Sahm
Crinetics Pharmaceuticals, Inc. $CRNX Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Crinetics Pharmaceuticals (CRNX) Stock Lags As Revenue Builds And Losses Deepen - Sahm
Crinetics Pharmaceuticals stock hits all-time high at 84.01 USD - Investing.com
Crinetics Pharmaceuticals (CRNX) On Vertex Deal Optimism And Results Looks Nearly Fully Valued - finance.yahoo.com
Crinetics Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Crinetics Pharmaceuticals stock hits all-time high at 84.01 USD By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 52-Week High After Better-Than-Expected Earnings - MarketBeat
Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis - Yahoo Finance
Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: Revenue Growth Surges by 2,873% Amidst Strong Biotech Potential - DirectorsTalk Interviews
CRNX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Is Crinetics Pharmaceuticals (CRNX) Undervalued After Q2 Earnings Miss? GF Score: 47/100, Revenue at $25.1M - GuruFocus
Crinetics Pharma earnings beat by $0.08, revenue topped estimates - Investing.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Issues Earnings Results - MarketBeat
Crinetics Pharmaceuticals 2026: Revenue $25.12M, EPS ($1.14) — 10-Q Summary - TradingView
Earnings Flash (CRNX) Crinetics Pharmaceuticals, Inc. Reports Q2 Revenue $25.1M, vs. FactSet Est of $14.8M - marketscreener.com
Farallon discloses 8.5% Crinetics stake in Schedule 13G/A (CRNX) - Stock Titan
Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal - The Business Journals
Janus Henderson Group PLC Has $164.23 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Bank of New York Mellon Corp Sells 46,291 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals (CRNX) holders to vote on $85-per-share cash sale to Vertex - Stock Titan
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target - Yahoo Finance
Crinetics Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Crinetics Pharmaceuticals (NASDAQ:CRNX) Cut to "Hold" at UBS Group - MarketBeat
CRNX Downgraded by UBS -- Price Target Raised to $85.00 - GuruFocus
UBS Downgrades Crinetics Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $85 From $55 - marketscreener.com
UBS downgrades Crinetics stock rating on Vertex acquisition By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals' (CRNX) "Neutral" Rating Reiterated at UBS Group - MarketBeat
Crinetics Pharmaceuticals Inc - TradingKey
CRNX|Crinetics Pharmaceuticals Inc|Price:83.865|Chg%:+0.135 - TradingKey
Crinetics Pharmaceuticals Inc (CRNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 12-Month HighStill a Buy? - MarketBeat
TradingKey - TradingKey
Crinetics Pharmaceuticals Inc (CRNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Crinetics Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CRNX - TradingView
Siren L.L.C. Raises Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—CRNX, SLP, NCSM, and PASG - Morningstar
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):